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Objectives: Polymorphisms in the lysosomal transporter encoded by the pfcrt gene directly impact on
Plasmodium falciparum susceptibility to aminoquinolines. The Lys76Thr mutation is the critical change conferring
chloroquine resistance in vitro and in vivo, but always occurs with additional non-synonymous changes in the
pfcrt coding sequence. We sought to better describe pfcrt polymorphisms distal to codon 76.
Methods: Small-volume samples (≤500 mL) of parasite-infected blood collected directly from malaria patients
presenting for treatment in Sudan and Tanzania were immediately preserved for RNA extraction. The pfcrt locus
was amplified from cDNA preparations by nested PCR and sequenced directly to derive full-length mRNA
sequences.
Results: In one of two sites in Sudan, two patients were found with an unorthodox spliced form of pfcrt mRNA in
which two exons were skipped, but it was not possible to test for the presence of the putative protein products of
these aberrant transcripts. Genomic DNA sequencing from dried blood spots collected in parallel confirmed the
presence of spliced pfcrt pseudogenes in a minority of parasite isolates. Full-length cDNA from conventionally
spliced mRNA molecules in all study sites demonstrated the existence of a variety of pfcrt haplotypes in East
Africa, and thus provides evidence of intragenic recombination.
Conclusions: The presence of pseudogenes, although unlikely to have any direct public health impact, may con-
found results obtained from simple genotyping methods that consider only codon 76 and the adjacent residues
of pfcrt.
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Introduction
Resistance of the malaria parasite Plasmodium falciparum to
antimalarial drugs has posed a serious threat to public health
in Africa in the past,1 and may do so again in the future.2
Molecular markers of resistance to chloroquine, pyrimethamine
and sulfadoxine were identified and validated some years after
the efficacy of these drugs had waned; the utility of markers
was thus mainly in gaining understanding of events that had
already happened. In the context of artemisinin-based combin-
ation therapy (ACT) being the mainstay of uncomplicated malaria
management worldwide, malaria researchers have recently
focused on the identification of candidate markers for diminished
efficacy of artemisinin and of the partner drugs used in ACT.3 Such
markers are needed as molecular tools for surveillance for the
purpose of preventing the global spread of resistant parasites
from foci of origin, and this objective has become more urgent
since the recent description in Cambodia and neighbouring
countries of parasites with reduced susceptibility to artemisinin
compounds.4,5
It is now well established that ACT selects for particular alleles
of two genes, pfmdr1 and pfcrt, both firmly associated with resist-
ance to the 4-aminoquinolines chloroquine and amodiaquine.
In a number of African studies of ACT efficacy in symptomatic
children and adults, the aminoquinoline-susceptible haplotypes
of these genes were significantly more common in recurrent
parasitaemia detected during follow-up after treatment with
the most commonly used ACT, artemether/lumefantrine.6 – 9
Encoding a transporter located in the parasite’s digestive vacu-
ole membrane, pfcrt is an important determinant of susceptibility
to antimalarial chemotherapy. Variant genes encoding a threo-
nine instead of a lysine at codon 76 (the K76T mutation) are highly
resistant to chloroquine in vitro and more likely to be present
in parasites surviving chloroquine or amodiaquine treatment
in vivo,10 – 13 but less likely to survive in ACT-treated malaria
patients.6 – 9 The gene encoding the PfCRT protein comprises 13
short exons interrupted by AT-rich introns, imposing technical
challenges when sequencing the gene from small-volume, non-
replenishable samples. Thus, available sequence data not
immediately adjacent to codon 76 have mostly been derived
from cDNA obtained from culture-adapted parasite lines.14,15
More information on polymorphisms across the full-length pfcrt
gene is therefore needed, particularly from in vivo studies of
treated malaria patients. In this study transcripts of the pfcrt
gene were isolated from peripheral blood collected directly from
symptomatic malaria cases prior to treatment in two East
African settings, and characterized by extended cDNA sequen-
cing, in order to reconstruct full genetic haplotypes present
in vivo. We report for the first time alternatively spliced forms
of pfcrt mRNA, and the presence of genomic intron-free pfcrt
ORF sequences, likely to represent processed—and probably
transcribed—pseudogenes.
Materials and methods
Study population
Peripheral blood samples for this study were collected as part of a trial of
artemether/lumefantrine efficacy in both adults and children, conducted
in New Halfa and Gedarif in eastern Sudan in 2006,9 and a pharmacokinetic
study of children aged 1–10 years treated with artemether/lumefantrine
for uncomplicated P. falciparum infection, performed in Fukayosi, Bagamoyo
district, Tanzania in 2006.16,17 Details of the study area, study design,
patient recruitment criteria, ethical considerations and treatment out-
come have been previously reported for both studies.
Sample collection and nucleic acid preparation
For RNA isolation and cDNA synthesis, in both Sudanese studies whole
blood was collected in EDTA tubes prior to treatment. A 60 mL aliquot of
each sample was mixed with 500 mL of TRI reagent (Sigma) and stored
initially at 2208C and later at 2808C once the field work was completed.
RNA was extracted by the TRI reagent protocol or the SV total RNA extrac-
tion kit (Promega) as per the manufacturers’ instructions and DNA
removed by digestion with deoxyribonuclease I. cDNA was synthesized
employing the Superscript III kit (Invitrogen) as per the manufacturer’s
recommendations, using random oligonucleotide hexamers to prime the
first-strand synthesis. In Fukayosi, from each patient 0.5 mL of whole
blood was collected in ribonuclease-free tubes containing 0.5 mL of PBS
and 1 mL of 2× Lysis Solution (Applied Biosystems), mixed by shaking
and stored directly on ice, then transported to Karolinska Institutet,
Sweden on dry ice and stored at 2208C. RNA isolation was performed
using the ABI 6100 machine according to the Applied Biosystems protocol
for isolation of total RNA from whole blood. Samples were thereafter
stored at2808C. cDNA was synthesized using random hexamers provided
in the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
For DNA extraction, pretreatment finger-prick blood samples were col-
lected onto glass fibre membranes (Wallac, Finland), dried and stored at
48C. DNA was extracted by the Chelexw method as previously described.9
Amplification and sequencing of the pfcrt gene
Full-length cDNA and genomic DNA (gDNA) of the pfcrt gene were amplified
in two overlapping PCR amplicons. Fragment 1 [86 nt of the 5′ untranslated
region (UTR), plus codons 1–247] was amplified with primers CRTP111 and
NG1_REV in the outer reaction and semi-nested with NG4_REV for frag-
ment 1. Fragment 2 (codons 220–424, plus 151 nt of the 3′ UTR) was amp-
lified with primers NG5_FOR and NG3_REV for the outer reaction and
NG2_FOR and NG3_REV for the nested reaction (Figure 1a). Non-specific
and incomplete single-stranded DNA was removed from PCR products
using EXO I exonuclease (Fermentas) prior to sequencing on both strands
using the amplification primers (ABI BigDye v3 Cycle Terminator kit). In add-
ition, two extra primers (NG6_REVand NG7_FOR; Table 1) were employed at
the 5′ and 3′ terminals, respectively, to sequence the full length of the gene.
For gDNA, additional sequencing reactions employing primers P11 (on
exon), P13 (crosses intron) and P17 (on intron) were performed.
Amplification and sequencing primers, and cycling conditions used, are
presented in Table 1. Analysis was performed as previously described.9
Results
The full-length cDNA sequence of the pfcrt gene, assembled from
two overlapping amplicons together comprising codons 1–424,
was successfully obtained from 26 and 35 of the isolates from
eastern Sudan and Bagamoyo district, respectively, while codons
1–220 were successfully sequenced in an additional 23 and 13
isolates, respectively.
Expression of an alternatively spliced variant of pfcrt
In two isolates from New Halfa, Sudan (samples 18 and 24), the
PCR amplifying cDNA from the 5′ segment of the pfcrt mRNA pro-
duced two products by gel electrophoresis: the expected 827 bp
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product and an amplicon of500 bp. In sample 24 this band was
more intense than the 827 bp product, while in sample 18 both
bands were of moderate intensity (Figure 2a). Direct sequencing
of the 500 bp PCR product for sample 24 revealed that, for the
majority of cDNA molecules amplified, exons 3 and 4 were com-
pletely absent, resulting in a truncated cDNA sequence (521 bp;
Figure 1b and Figure 2b). This transcript, if translated, encodes a
putative 322 amino acid hypothetical protein, which would be
(a)
(b)
Figure 1. Amplification strategy of the pfcrt gene employed in this study. (a) Amplification of the PF3D7_0709000 gDNA of the pfcrt gene, exons (black
boxes), introns (solid grey lines) and UTR (grey boxes with black fill). Fragment 1 (solid black line) and fragment 2 (solid grey line) are indicated beneath
the gene map. PCR primer pairs used to amplify the whole gene (in both gDNA and cDNA) are indicated by horizontal arrows. Primers NG6_REV and
NG7_FOR were used to sequence the UTR. Locations of Q10K and D24Y polymorphisms are indicated with arrows. Intron deletion region in gDNA is
indicated. (b) cDNA amplified from the pfcrt gene. Upper transcript map is the reference PF3D7_0709000 pfcrt cDNA. Lower map is the variant pfcrt
cDNA amplified in sample 24. Black rectangles represent the sequenced transcribed exons. Asterisks represent the non-transcribed (spliced) exons.
Grey rectangles represent the putative mRNA downstream from codon 220; this region was not sequenced from cDNA but inferred from gDNA sequence.
Table 1. Primer sequences and PCR cycling conditions for amplifying and sequencing full-length pfcrt
Gene PCR primer sequence 5′ to 3′ Cycling conditions
Product
size (bp)
pfcrt fragment 1 (exons 1–4) outer PCR 948C3 min, (948C1 min; 458C1 min, 658C1 min)×30
cycles, 658C10 min
873
CRTP1: CCG TTA ATA ATA AAT ACA CGC AG
NG1_REV: GGA TAC CAT AGC ATT TAA TC
nested PCR 948C3 min, (948C1 min; 508C1 min, 658C1 min)×30
cycles, 658C10 min
827
CRTP1: CCG TTA ATA ATA AAT ACA CGC AG
NG4_REV: AGC ATT TAA TCT TAA AAT GTC
pfcrt fragment 2 (exons 4–13) outer PCR 948C3 min, (948C1 min; 508C1 min, 658C1 min)×30
cycles, 658C10 min
874
NG5_FOR: CTC GGA GCA GTT ATT ATT G
NG3_Rev: ATT CCT TAT AAA GTG TAA TGC GA
nested PCR 948C3 min, (948C1 min; 508C1 min, 658C1 min)×30
cycles, 658C10 min
827
NG2_FOR: GCT CTT GTA GAA ATG AAA TTA TC
NG3_REV: ATT CCT TAT AAA GTG TAA TGC GA
5′ and 3′ UTR sequencing primers NG6_REV: GAA CAT AAT CAT ACA AAT A
NG7_FOR: CCG TGT AGG AAA TAT TAT CT
Sequencing primers for confirming
intron skipping
P11: TCCTTTTTCCAATTGTTCACTTC
P13: GACGGAGCATGGGTAAGAAG
P17: CAAATGGCTTGTTCGTTCATAA
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102 amino acids shorter than the canonical PfCRTencoded by the
3D7 clone reference (PF3D7_0709000, www.PlasmoDB.org). It is
interesting to note that exons 2 and 5 are both type 0 exons,
which means that splicing occurs exactly on codon triplet bound-
aries (i.e. at the third nucleotide), and so the removal of both
exons 3 and 4 does not change the reading phase of the codons.
Figure 1(b) illustrates the predicted structure of the full-length
spliced cDNA. The sequence of pfcrt mRNA in all remaining patient
samples from Gedarif and Fukayosi displayed the expected spliced
form. This suggests that the splice variant is not always present.
Intron deletion in genomic copies of pfcrt
In order to investigate whether the observed splicing reflects rear-
rangements at the genomic level, and to address whether pfcrt
introns are structured differently in these samples, DNA was
extracted from glass fibre membranes by the Chelex method,
which does not preserve RNA, from samples 18 and 24, and
from three additional randomly selected samples for comparison,
22, 5 and 75 from New Halfa. These were subjected to amplifica-
tion and sequencing, which was successful only for the 3′ region
of the pfcrt gene, coding for the protein carboxy-terminus.
Interestingly, amplification produced two PCR products of unex-
pected sizes: a 600 bp product and an 450 bp product in sam-
ples 18 and 24, and also in one of the comparators, 22.
For each of these isolates, the two PCR products were excised
from agarose gels following electrophoresis, purified and
sequenced. Four primers (NG2_FOR, P11, P13 and P17) located in
this region were employed for sequencing these products. Direct
sequencing of the 600 bp PCR product revealed complete removal
of introns, with the analysed partial genomic sequence found to be
identical to the predicted mRNA sequence. Figure 3 shows the par-
tial PfCRT amino acid sequence encoded by an intronless gDNA
segment amplified from samples 18 and 24. Interpretable
sequence data were not obtained from the 450 bp amplicon in
any of these isolates. Thus some P. falciparum isolates from
New Halfa harbour additional genome copies of pfcrt that lack
introns. We were not able to demonstrate that these unusual gen-
omic pfcrt loci were the origin of the unusual transcripts identified
in the previous cDNA analysis, and these may be inactive, pro-
cessed pseudogenes that are not expressed. Alternatively, these
may be transcribed by blood stage parasites, giving rise to the
unconventionally spliced transcripts observed.
Haplotypes deduced from pfcrt transcript sequences
cDNA sequence data were used to construct extended haplotypes
for the pfcrt locus in each P. falciparum isolate that exhibited
the wild-type splicing pattern. Two new polymorphisms were
observed in a single isolate from Sudan: the non-synonymous
nucleotide change C28A generating a Gln to Lys mutation at
codon 10 (Q10K), and the nucleotide change G70T resulting in
an Asp to Tyr mutation at codon 24 (D24Y). This codon 24 poly-
morphism was also observed in three isolates from Tanzania.
Using the single-letter amino acid nomenclature, the following
non-synonymous pfcrt mutations were observed in addition to
codons 10 and 24: M74I, N75E, K76T, A220S, Q271E, N326S and
R371I. (In the following paragraphs, only these variant positions
are considered.)
Among the 23 Sudanese isolates where only the 5′-region of
the cDNA was fully sequenced, the wild-type haplotype MNKA
(at codons 74–76 and 220) was present in 4 (17.4%), and the
remaining 19 isolates carried the mutant IETS haplotype, asso-
ciated with chloroquine resistance in Africa. Of the 26 isolates
for which full-length transcript sequences were obtained,
chloroquine-resistant haplotypes dominated, with five distinct
(a)
(b)
Figure 2. (a) Ethidium-bromide-stained agarose gels of RT–PCR products of N-terminus of pfcrt mRNA. Lane 1, Hyper Ladder IV (100 bp); lanes 2–24,
clinical samples. Arrows indicate samples 18 and 24 in which two RT–PCR products were observed, the expected 827 bp and the 521 bp truncated
product. (b) Predicted amino acid sequence of abnormally spliced pfcrt mRNA from patient 24. The amino acid sequence of exons 1 and 2 is shown.
The arrow indicates the splice site at the end of exon 2, followed by the sequence at the beginning of exon 5.
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full-length haplotypes (Figure 3). A single isolate displayed the
reference (wild-type) haplotype MNKAQNR at codons 74 –76,
220, 271, 326 and 371. Importantly, two individuals in Sudan har-
boured parasites with hybrid haplotypes, IETSQNR and IETSQNI,
indicative of intragenic recombination within the pfcrt locus in
this population.
Among the 13 isolates from Fukayosi, Tanzania, for which only
the 5′-region was sequenced, the wild-type MNKA at codons 74–
76 and 220 was the predominant allele, being present in 7 isolates
(53.8%), with 3 (23.1%) carrying the IETS haplotype. Three
patients (23.1%) had a mixture of both the IET and MNK, all of
whom carried the mutant 220S. A total of 35 isolates were suc-
cessfully sequenced for the full-length transcript (Figure 3). Two
hybrid haplotypes, IETSQNR and MNKAQNI at codons 74–76,
220, 271, 326 and 371, were detected in a single Tanzanian isolate
each. Thus in both Sudan and Tanzania, recombinant pfcrt alleles
comprising sequence elements of both chloroquine-resistant and
wild-type pfcrt were observed. The prevalence of each haplotype
observed in both Sudan and Tanzania is presented in Figure 4.
Discussion
The CRT membrane transporter is an important modulator of
parasite response to antimalarial chemotherapy, and yet few
studies have addressed the structure or abundance of pfcrt tran-
scripts in natural P. falciparum infections. Here, we sequenced
cDNA amplified from pfcrt mRNA present in P. falciparum-infected
peripheral blood samples taken prior to treatment from malaria
patients in eastern Sudan and coastal Tanzania. This approach
provided evidence that, in vivo, peripheral blood parasites express
alternatively spliced pfcrt mRNA, the first such demonstration
either in vivo or in vitro, and that naturally occurring parasite gen-
omes can harbour additional pfcrt copies in the form of spliced
pseudogenes. Although these extra gene copies may be the
source of the unorthodox pfcrt mRNA molecules we detected,
additional studies are needed to confirm a direct relationship.
Further, we determined extended pfcrt haplotypes, identifying
new polymorphisms at codons 10 and 24, and providing the first
evidence that chloroquine-resistant and chloroquine-susceptible
forms of pfcrt recombine in natural parasite populations.
The unusual variant transcript of pfcrt described here was
detected in clinical isolates from only one of two study sites
in eastern Sudan, and did not occur among the sequenced
Tanzanian isolates. Due to the complete removal of exons 3 and
4 (amino acids 121–222), this transcript encodes a significantly
altered putative CRT. This shorter protein will not include the
transmembrane domains 3–5, while having a drastically trun-
cated transmembrane domain 6 (Figure 5). Also, this change
obliterates three polymorphic amino acid positions (T152A,
S163R and the canonical S220A), each probably relevant to CRT
function, as they have been associated with different responses
of the parasite to several drugs, including chloroquine.10,18
However, we have no evidence to date that such a CRT protein
is expressed from the alternatively spliced mRNA, and all isolates
expressing this variant transcript also expressed the normally
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Figure 4. Frequency of pfcrt haplotypes in cDNA from isolates in eastern
Sudan (n¼49) and Tanzania (n¼40). Number of observations of each
haplotype defined at codons 74–76 and 220 (amino-terminus and
full-length data) and 271, 326 and 371 (full-length data only). Data
from isolates with multiple genotypes at the pfcrt locus were not included.
Figure 3. Clustal alignment of predicted amino acid sequences of nine distinct pfcrt haplotypes identified by sequencing cDNA generated directly from
peripheral blood parasite mRNA. Contributing data were derived from two New Halfa isolates with identical splice variant transcripts (Sp1), 26 full-length
cDNA sequences from New Halfa and Gedaref, Sudan, and 35 full-length cDNA sequences from Fukayosi, Tanzania. Haplotype labels indicate predicted
chloroquine resistance status (CQS, susceptible; CQR, resistant). Vertical gaps in the alignment indicate invariant sequence tracts not included. Labels
under the alignment refer to variant positions (shaded).
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spliced, full-length pfcrt transcript. As exons 2 and 5 are spliced
precisely in-frame with codon boundaries (known as type 0
splicing), the downstream sequence frame is maintained, such
that the alternative splicing event can generate mRNA molecules
that encode in-frame putative polypeptides. This also raised the
question as to whether the alternative spliced format of pfcrt
and the full-length mRNA were both being expressed from
the established pfcrt locus on chromosome 7 (exemplified by
PF3D7_0709000).
Alternative splicing is an important mechanism by which
precursor mRNAs are transcribed into several forms of mature
mRNAs,19,20 leading to multiple polypeptides encoded by a single
gene, and the generation of plurifunctional variant protein iso-
forms.21 The first report of a spliced variant mRNA in P. falciparum
was the 41-3 gene encoding a variable antigen involved
in immune regulation and sought as a vaccine candidate.22
Further examples are the guanylyl cyclase gene involved in the
signalling pathway of male gametogenesis,23 the erythrocyte-
binding protein MAEBL24 and a CDK-related protein kinase 6.25
Recent transcriptomic studies have identified further variable spli-
cing events for various P. falciparum genes in laboratory-cultured
clones such as 3D7 and NF54,26,27 but there have been no reports
of alternative splicing in the pfcrt gene in laboratory lines or in vivo.
Interestingly, Otto et al.28 described four new splicing events on
chromosome 7, but none of these encompassed the pfcrt locus.
In attempting to understand the genomic origin of the variant
cDNA sequences we observed, which corresponded to the 5′ half
of the normal pfcrt mRNA, the 3′ half of an additional genomic
pfcrt locus in which all introns were missing was identified in
parasite gDNA amplified from dried filter-paper blood spots. To
our knowledge, this is the first description of pseudogenes derived
from drug resistance-associated functional genes in Plasmodium.
A plausible explanation for our observations, which we were
unable to confirm with the material available, is that the intron-
less pfcrt locus we have described is a classic pseudogene
that has arisen in this parasite population, and is transcribed,
as P. falciparum pseudogenes frequently are.28 As such it may
have no significant effect on parasite responses to antimalarial
drugs, despite being expressed in peripheral blood parasites,
although an effect on regulation of transcription from the
native pfcrt locus cannot be ruled out. The unusual cDNA we
sequenced encompassed the region of pfcrt around the codon
76 polymorphism, suggesting the same may be true for the add-
itional pfcrt pseudogene locus; this is therefore very likely to con-
tribute to genotyping analysis of parasite DNA from peripheral
blood. It remains possible that such loci are widespread, and
have been part of the ‘signal’ obtained whenever field samples
are genotyped at this locus, whether by PCR-RFLP, qPCR or direct
sequencing.11,15,29 It is very important that this possible source of
confounding of genotyping studies is investigated thoroughly.
Interestingly, the pseudogene encodes the mutant 76Thr allele,
and so represents an evolutionary event that occurred since
chloroquine and related aminoquinolones came into use in the
1940s. It is fascinating to speculate that, as the codon 76 muta-
tion becomes less prevalent due to the withdrawal of chloroquine
in Africa, these pseudogenes will remain as genomic ‘fossils’,
which may nevertheless provide a source of the mutant sequence
that could be reactivated by recombination should chloroquine
pressure be resumed in the future. In this context, it should be
noted that evidence suggests that considerable variability was
present in the pfcrt locus before the era of chloroquine exposure.30
CRT codons 72–76 are currently under opposite selection pres-
sure by artemisinins and partner drugs currently employed in
ACT.8,31 This pressure for parasite survival may select specific
adaptive changes in gene structure, as well as changes in the
regulation and expression of pfcrt and other key loci such as
pfmdr1.32 – 34 This adaptation may include the loss of introns, as
reported for fission yeast and mice,35 and the potential gain of
new functions. In fact, evidence is gathering that a pseudogene
can actually have critical functions, and in some cancers can
regulate the ‘parent’ locus.36,37 Finally, our data describe two
new polymorphic codons, for amino acids 10 and 24, and provide
the first evidence of recombination among chloroquine-resistant
and chloroquine-susceptible haplotypes of pfcrt in both Sudan
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Figure 5. A possible linear arrangement of transmembrane regions in the full-length CRT protein (a) and putative truncated CRT protein encoded by
alternative-spliced pfcrt mRNA from Sudanese malaria patients (b). Transmembrane regions are depicted as rectangles; blue denotes presence in
putative truncated form of CRT and white denotes presence only in full-length CRT. Freeform blue line denotes extramembrane polypeptide tracts in
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and Tanzania. Such events may indicate that pfcrt genes are still
evolving in African parasite populations, generating further het-
erogeneity in the structure of the CRT protein, and this diversity
is likely to be under active selection by ongoing ACT pressure
across the continent.
Conclusions
In this study we describe aberrant spliced pfcrt transcripts and
confirm the presence of pfcrt pseudogenes in a small number of
patient parasite isolates. We also provide evidence from both
Sudan and Tanzania that hybrid forms of pfcrt with sequence
characteristics of both chloroquine-resistant and wild-type alleles
are present in natural populations, probably due to meiotic
recombination. A weakness of our study is that the unusual tran-
scripts and alleles of pfcrt were detected in non-replenishable
parasite RNA and DNA, and so confirmatory analyses were not
possible. Similarly, no phenotypic analysis of any of the parasite
isolates was carried out. However, as the variant alleles of pfcrt
were identified in more than one individual, and from both
mRNA and gDNA sequences, we are confident that these para-
sites were present in New Halfa. Further studies of pfcrt cDNA
sequences from patient peripheral blood are needed to explore
this phenomenon further.
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